1. GPCR/G Protein Neuronal Signaling Apoptosis PI3K/Akt/mTOR
  2. Cholecystokinin Receptor Apoptosis PI3K Akt
  3. Sincalide

Sincalide  (Synonyms: Cholecystokinin octapeptide; CCK-8; SQ19844)

Cat. No.: HY-P0093 Purity: 99.51%
COA Handling Instructions

Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Sincalide Chemical Structure

Sincalide Chemical Structure

CAS No. : 25126-32-3

Size Price Stock Quantity
1 mg USD 110 In-stock
5 mg USD 300 In-stock
10 mg USD 480 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Sincalide:

Top Publications Citing Use of Products

View All Cholecystokinin Receptor Isoform Specific Products:

View All PI3K Isoform Specific Products:

View All Akt Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK[1][2][3].

In Vitro

Sincalide (Cholecystokinin octapeptide, CCK‐8), as a novel cardiovascular hormone, has a significant inhibitory effect on myocardial fibrosis in noninfarcted areas. CCK‐8 also plays a positive role in fighting inflammation, apoptosis and collagen deposition. CCK‐8 protects H9c2 cardiomyoblasts from Ang II‐induced apoptosis partly via activation of the CCK1 receptor and the phosphatidyqinositol‐3 kinase/protein kinase B (PI3K/Akt) signaling pathway[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[3]

Cell Line: H9c2 cells
Concentration: 0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time: 24 h
Result: Attenuated Ang II‐induced toxicity in H9c2 cells

Apoptosis Analysis[3]

Cell Line: H9c2 cells
Concentration: 0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time: 24 h
Result: Decreased apoptotic cells, and prevented Ang II‐induced cytotoxicity that involves modulation of the PI3K/Akt pathway.

Western Blot Analysis[3]

Cell Line: H9c2 cells
Concentration: 0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time: 24 h
Result: Expressed the protein and mRNAs of CCK and both its receptors in H9c2 cells.

RT-PCR[3]

Cell Line: H9c2 cells
Concentration: 0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
Incubation Time: 24 h
Result: Increased the protein and mRNA expression levels of CCK and decreased CCK 1 receptor expression levels at both the protein and mRNA levels with Ang II stimulation markedly.
In Vivo

Sincalide (Cholecystokinin octapeptide, CCK‐8) (i.p.; 50 μg/kg/d; for 4 weeks) alleviates fibrosis in the noninfarcted regions and delay the left ventricular remodeling and the progress of heart failure in a MI rat model[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MI rat model[4]
Dosage: 50 μg/kg
Administration: i.p.; 50 μg/kg/d; for 4 weeks
Result: Had significant inhibitory effect on myocardial fibrosis in noninfarcted areas.
Clinical Trial
Molecular Weight

1143.27

Formula

C49H62N10O16S3

CAS No.
Appearance

Solid

Color

White to off-white

Sequence Shortening

D-{SO3H-Tyr}-MGWMDF-NH2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture and light, under nitrogen

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Solvent & Solubility
In Vitro: 

H2O : 50 mg/mL (43.73 mM; ultrasonic and adjust pH to 11 with NH3·H2O)

DMF : 50 mg/mL (43.73 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.8747 mL 4.3734 mL 8.7468 mL
5 mM 0.1749 mL 0.8747 mL 1.7494 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMF    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (2.19 mM); Clear solution

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMF 1 mM 0.8747 mL 4.3734 mL 8.7468 mL 21.8671 mL
5 mM 0.1749 mL 0.8747 mL 1.7494 mL 4.3734 mL
10 mM 0.0875 mL 0.4373 mL 0.8747 mL 2.1867 mL
15 mM 0.0583 mL 0.2916 mL 0.5831 mL 1.4578 mL
20 mM 0.0437 mL 0.2187 mL 0.4373 mL 1.0934 mL
25 mM 0.0350 mL 0.1749 mL 0.3499 mL 0.8747 mL
30 mM 0.0292 mL 0.1458 mL 0.2916 mL 0.7289 mL
40 mM 0.0219 mL 0.1093 mL 0.2187 mL 0.5467 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Sincalide
Cat. No.:
HY-P0093
Quantity:
MCE Japan Authorized Agent: